Cargando…
Circulating plasma microRNAs in colorectal neoplasia: A pilot study in assessing response to therapy
INTRODUCTION: Current serological surveillance markers to monitor colorectal cancer (CRC) or colorectal advanced adenomas (CAA) are hampered by poor sensitivity and specificity. The aim of this study is to identify and validate a panel of plasma microRNAs which change in expression after resection o...
Autores principales: | O'Brien, Stephen J, Netz, Uri, Hallion, Jacob, Bishop, Campbell, Stephen, Vincent, Burton, James, Paas, Mason, Feagins, Kayla, Pan, Jianmin, Rai, Shesh N., Galandiuk, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720092/ https://www.ncbi.nlm.nih.gov/pubmed/33285367 http://dx.doi.org/10.1016/j.tranon.2020.100962 |
Ejemplares similares
-
Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative
Colitis
por: Netz, Uri, et al.
Publicado: (2018) -
Long non-coding RNA (lncRNA) and epithelial-mesenchymal transition (EMT) in colorectal cancer: a systematic review
por: O’Brien, Stephen J., et al.
Publicado: (2020) -
Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma
por: O’Brien, Stephen J., et al.
Publicado: (2021) -
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017) -
The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2
por: Carter, Jane V., et al.
Publicado: (2019)